Technical analysis of Hepion Pharmaceuticals, Inc. (HEPA): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease.
Price Performance
| 1 month | -7.73% |
| 3 months | +15.33% |
| Year-to-date | +15.33% |
| 1 year | +15.33% |
| 3 years | -99.98% |
| 5 years | -100.00% |
52-Week Range
| 52-week High | $0.11 |
| 52-week Low | $0.03 |
| Avg Volume (90d) | 30K |
Technical Indicators
| SMA 50 | $0.06 |
| SMA 200 | $0.06 |
| 30-day Volatility (annualised) | 315.7% |
| Price vs SMA 50 | +6.6% |
| Price vs SMA 200 | +15.4% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $0.07 | |
| 2025-11 | $0.07 | -3.0% |
| 2025-12 | $0.06 | -7.7% |
| 2026-01 | $0.04 | -41.7% |
| 2026-02 | $0.04 | +14.3% |
| 2026-03 | $0.06 | +42.0% |
| 2026-04 | $0.06 | +10.0% |
| 2026-05 | $0.07 | +5.8% |
| 2026-06 | $0.07 | +2.6% |
| 2026-07 | $0.05 | -32.4% |
| 2026-08 | $0.08 | +73.2% |
| 2026-09 | $0.07 | -13.0% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | $144M |
| 2026-09-14 | | $898M |
Price
| Price | $0.07 |
| Market Cap | $1M |
| Exchange | OTC |
| Country | US |
Valuation Ratios
| Price / Book | 0.88 |
| EV / EBITDA | 0.34 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 3.91 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -114.78 |